Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from CalciMedica ( (CALC) ) is now available.
On June 24, 2025, CalciMedica, Inc. held its 2025 Annual Meeting of Stockholders, where stockholders approved an amendment to the company’s 2023 Equity Incentive Plan, increasing the number of shares authorized for issuance by 600,000. Additionally, stockholders elected three Class I directors to serve until 2028 and ratified the appointment of Baker Tilly US, LLP as the company’s principal independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (CALC) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CalciMedica stock, see the CALC Stock Forecast page.
Spark’s Take on CALC Stock
According to Spark, TipRanks’ AI Analyst, CALC is a Underperform.
CalciMedica’s low stock score reflects its financial challenges, including zero revenue and negative cash flows. However, technical indicators suggest the stock is currently oversold, providing a potential entry point for risk-tolerant investors. The promising results from the Auxora trial offer a positive outlook, potentially improving future financial performance.
To see Spark’s full report on CALC stock, click here.
More about CalciMedica
Average Trading Volume: 26,445
Technical Sentiment Signal: Sell
Current Market Cap: $21.94M
Learn more about CALC stock on TipRanks’ Stock Analysis page.